Yue XF et al. |
Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. |
1992 |
Zhongguo Yao Li Xue Bao |
pmid:1442109
|
Fan YJ et al. |
[Effect of maytansine on the cell cycle of Ehrlich ascites carcinoma cells in mice]. |
1985 |
Zhongguo Yao Li Xue Bao |
pmid:3158164
|
Yang JL et al. |
[Antitumor activity of trewiasine in vitro and in vivo]. |
1988 |
Zhongguo Yao Li Xue Bao |
pmid:3256213
|
Wang XF et al. |
[Studies on the antitumor constituents of Maytenus confertiflora Luo et Chen (Celastraceae). II. Isolation and characterization of maytansine and maytanprine from the stems]. |
1981 |
Yao Xue Xue Bao |
pmid:7324964
|
Fan YJ et al. |
[Use of 1,2:5,6-dianhydrogalactitol in combination with maytansine in experimental tumor therapy]. |
1983 |
Yao Xue Xue Bao |
pmid:6677049
|
Vilela MD et al. |
Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. |
2018 |
World Neurosurg |
pmid:29274446
|
Niell HB et al. |
Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer. |
1985 |
Urology |
pmid:2579500
|
Milowsky MI et al. |
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. |
2016 |
Urol. Oncol. |
pmid:27765518
|
Roviello G et al. |
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. |
2016 |
Tumour Biol. |
pmid:26566626
|
Faião-Flores F et al. |
Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. |
2013 |
Tumour Biol. |
pmid:23341182
|
De Angelis C et al. |
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. |
2013 May-Jun |
Tumori |
pmid:24158083
|
Poon KA et al. |
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. |
2013 |
Toxicol. Appl. Pharmacol. |
pmid:24035823
|
Wehrli W |
Ansamycins. Chemistry, biosynthesis and biological activity. |
1977 |
Top Curr Chem |
pmid:74108
|
Hull RN et al. |
Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. |
1977 |
Thromb. Res. |
pmid:18812
|
Liang Y et al. |
A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. |
2017 |
Theranostics |
pmid:28900511
|
Vankemmelbeke M and Durrant L |
Third-generation antibody drug conjugates for cancer therapy--a balancing act. |
2016 |
Ther Deliv |
pmid:26893243
|
Sieber SM et al. |
Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. |
1978 |
Teratology |
pmid:694777
|
Kosmin M et al. |
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. |
2017 |
Target Oncol |
pmid:28110417
|
Diéras V and Bachelot T |
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. |
2014 |
Target Oncol |
pmid:23852665
|
Iwasaki S |
[Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands]. |
1993 |
Tanpakushitsu Kakusan Koso |
pmid:8210422
|
Janjigian YY and Braghiroli MI |
Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. |
2017 |
Surg. Oncol. Clin. N. Am. |
pmid:28279471
|
Cox K et al. |
Emerging Therapeutic Strategies in Breast Cancer. |
2017 |
South. Med. J. |
pmid:28973703
|
Bhardwaj AS et al. |
A case of vasculitis in a breast cancer patient treated with T-DM1. |
2014 |
Semin. Oncol. |
pmid:25440614
|
Müller P et al. |
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. |
2015 |
Sci Transl Med |
pmid:26606967
|
Shen K et al. |
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. |
2016 |
Sci Rep |
pmid:26979925
|
Pan W et al. |
Asm8, a specific LAL-type activator of 3-amino-5-hydroxybenzoate biosynthesis in ansamitocin production. |
2013 |
Sci China Life Sci |
pmid:23832249
|
Ito Y |
[Progress of molecularly targeted therapy for breast cancer]. |
2012 |
Rinsho Ketsueki |
pmid:22687976
|
Lin CM et al. |
Binding of maytansine to tubulin: competition with other mitotic inhibitors. |
1981 |
Res. Commun. Chem. Pathol. Pharmacol. |
pmid:7255878
|
Lanshoeft C et al. |
Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. |
2016 |
Rapid Commun. Mass Spectrom. |
pmid:26969923
|
Lazar AC et al. |
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15945030
|
Gurtner K et al. |
Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. |
2012 |
Radiother Oncol |
pmid:22100655
|
Marcoux J et al. |
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. |
2015 |
Protein Sci. |
pmid:25694334
|
Wang L et al. |
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. |
2005 |
Protein Sci. |
pmid:16081651
|
Kubizek F et al. |
Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges? |
2017 |
Protein Pept. Lett. |
pmid:28741467
|
Sinha S and Jain S |
Natural products as anticancer agents. |
1994 |
Prog Drug Res |
pmid:7916160
|
Arvanitis CD et al. |
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. |
2018 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:30150398
|
Field JJ et al. |
A previously undescribed tubulin binder. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25187564
|
Prota AE et al. |
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. |
2014 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:25114240
|
Liu C et al. |
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. |
1996 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:8710920
|
Baskin F et al. |
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. |
1981 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:6943568
|
Rai SS and Wolff J |
The C terminus of beta-tubulin regulates vinblastine-induced tubulin polymerization. |
1998 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:9539723
|
Yu TW et al. |
The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. |
2002 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:12060743
|
Ismaili N et al. |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. |
2013 |
Presse Med |
pmid:23721860
|
Venghateri JB et al. |
Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. |
2013 |
PLoS ONE |
pmid:24124473
|
Chung YC et al. |
Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). |
2015 |
PLoS ONE |
pmid:26172389
|
Beerli RR et al. |
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. |
2015 |
PLoS ONE |
pmid:26132162
|
Goldmacher VS et al. |
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. |
2015 |
PLoS ONE |
pmid:25671541
|
Pullen CB et al. |
Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. |
2003 |
Phytochemistry |
pmid:12620351
|
Wings S et al. |
A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. |
2013 |
Phytochemistry |
pmid:22795602
|
Hinow P et al. |
Modeling the effects of drug binding on the dynamic instability of microtubules. |
2011 |
Phys Biol |
pmid:21836336
|
Jerjian TV et al. |
Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. |
2016 |
Pharmacotherapy |
pmid:26799352
|
Hamel E |
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. |
1992 |
Pharmacol. Ther. |
pmid:1287674
|
Squires H et al. |
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
2016 |
Pharmacoeconomics |
pmid:26892972
|
Lai KC et al. |
Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. |
2015 |
Pharm. Res. |
pmid:25630819
|
Wood AC et al. |
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. |
2013 |
Pediatr Blood Cancer |
pmid:23798344
|
Wang L et al. |
Formal total synthesis of N-methylmaysenine. |
2009 |
Org. Lett. |
pmid:19296671
|
Meyer A et al. |
Chemoenzymatic approaches toward dechloroansamitocin P-3. |
2007 |
Org. Lett. |
pmid:17378571
|
Frenzel T et al. |
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. |
2006 |
Org. Lett. |
pmid:16381586
|
Mancuso L et al. |
Bioreduction of aryl azides during mutasynthesis of new ansamitocins. |
2013 |
Org. Lett. |
pmid:23981134
|
van Boxtel W et al. |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. |
2017 |
Oral Oncol. |
pmid:28673692
|
Riechelmann H et al. |
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. |
2008 |
Oral Oncol. |
pmid:18203652
|
Montero JC et al. |
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. |
2015 |
Oncotarget |
pmid:26336133
|
Nonagase Y et al. |
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. |
2016 |
Oncotarget |
pmid:27768588
|
Raja SM et al. |
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. |
2016 |
Oncotarget |
pmid:26859680
|
Pegram M |
Treatment combinations for HER2-positive breast cancer. |
2013 |
Oncology (Williston Park, N.Y.) |
pmid:23781688
|
Ranson M and Sliwkowski MX |
Perspectives on anti-HER monoclonal antibodies. |
2002 |
Oncology |
pmid:12422051
|
Mujagić H and Mujagić Z |
Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton. |
1991 |
Oncology |
pmid:2023698
|
Lynce F et al. |
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. |
2017 |
Oncologist |
pmid:28314836
|
Kan S et al. |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. |
2015 |
Oncol. Rep. |
pmid:25976081
|
Yamashita-Kashima Y et al. |
Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. |
2013 |
Oncol. Rep. |
pmid:23783223
|
Hussar DA |
New drugs 2014, part 3. |
2014 |
Nursing |
pmid:25153167
|
Johnson MS |
The top 10 drug trends right now. |
2013 |
Nurs Manage |
pmid:23764906
|
Carlson JA et al. |
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. |
2014 |
Neuro-oncology |
pmid:24497407
|
Ponte JF et al. |
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. |
2016 |
Neoplasia |
pmid:27889646
|
Wright J |
Nanotechnology: Deliver on a promise. |
2014 |
Nature |
pmid:24870822
|
Higashide E et al. |
Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. |
1977 Dec 22-29 |
Nature |
pmid:593392
|
Eisenstein M |
Medicine: Eyes on the target. |
2015 |
Nature |
pmid:26580159
|
Wei GZ et al. |
A new antitumour ansamitocin from Actinosynnema pretiosum. |
2010 |
Nat. Prod. Res. |
pmid:20582809
|
Siyu-Mao et al. |
Two novel ansamitocin analogs from Actinosynnema pretiosum. |
2013 |
Nat. Prod. Res. |
pmid:23061718
|
Allison M |
Can cancer clinical trials be fixed? |
2011 |
Nat. Biotechnol. |
pmid:21221090
|
Shen BQ et al. |
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. |
2012 |
Nat. Biotechnol. |
pmid:22267010
|
DeFrancesco L |
Drug pipeline: 1Q13. |
2013 |
Nat. Biotechnol. |
pmid:23752422
|
Beck A et al. |
Strategies and challenges for the next generation of antibody-drug conjugates. |
2017 |
Nat Rev Drug Discov |
pmid:28303026
|
Zolot RS et al. |
Antibody-drug conjugates. |
2013 |
Nat Rev Drug Discov |
pmid:23535930
|
Villanueva MT |
Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. |
2014 |
Nat Rev Clin Oncol |
pmid:24913372
|
Kang Q et al. |
Biosynthesis of 3,5-AHBA-derived natural products. |
2012 |
Nat Prod Rep |
pmid:22193711
|
Menchon G et al. |
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. |
2018 |
Nat Commun |
pmid:29844393
|
Adams SR et al. |
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. |
2016 |
Nat Commun |
pmid:27698471
|
Zhong P et al. |
cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. |
2017 |
Nanotechnology |
pmid:28574851
|
He X et al. |
Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. |
2017 |
Nano Lett. |
pmid:28758755
|
Teicher BA and Doroshow JH |
The promise of antibody-drug conjugates. |
2012 |
N. Engl. J. Med. |
pmid:23134386
|
Verma S et al. |
Trastuzumab emtansine for HER2-positive advanced breast cancer. |
2012 |
N. Engl. J. Med. |
pmid:23020162
|
Hamblett KJ et al. |
Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. |
2016 |
Mol. Pharm. |
pmid:27248573
|
Hong EE et al. |
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. |
2015 |
Mol. Pharm. |
pmid:25856201
|
Widdison W et al. |
Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. |
2015 |
Mol. Pharm. |
pmid:25826705
|
Salomon PL and Singh R |
Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. |
2015 |
Mol. Pharm. |
pmid:25738394
|
Fishkin N |
Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. |
2015 |
Mol. Pharm. |
pmid:25738231
|
Goldmacher VS et al. |
Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. |
2015 |
Mol. Pharm. |
pmid:25635630
|
Barginear MF et al. |
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. |
2012 |
Mol. Med. |
pmid:23196784
|
Lopus M et al. |
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. |
2010 |
Mol. Cancer Ther. |
pmid:20937594
|